logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: Today’s Highlights

Yesterday's Prohost Stocks' Performances: NBIX UP $11.85; JUNO UP $11.60 and EXEL UP $1.35

EXELIXIS For Exelixis’ excellent news, please read our latest article, "Exelixis’ (EXEL) Exceptional Financial Results and Corporate Achievements", under Today’s Highlights NEUROCRINE BIOSCIENCE Prohost Picked this firm on April 24, 2017, at $51 (see the Prohost Portfolio in the Prohost...

Read More

November 3, 2017

0

Has the Time Come for Array Biopharma to Start Rallying?

At the European Society of Cardiology Congress 2016 in Rome, Italy, Array Biopharma (ARRY) presented good results from a Phase 2 study of its drug ARRY-797 - an oral, selective p38 mitogen-activated protein kinase inhibitor for patients with a rare...

Read More

August 31, 2016

0

About Nymox Pharmaceutical Drug Fexapotide for the Prevention of Prostate Cancer

Benign Prostate Hypertrophy (BPH) Is Fexapotide the Safest and Effective Prostate Cancer Preventative? That’s what Nymox Pharmaceutical (NYMX) announced in its recent press release stating that results from from 7-year prospective placebo controlled double blind studies of treatment of 995...

Read More

August 25, 2016

0

Incyte’s promising trial results and its plans to accelerate its future growth

Incyte (INCY) announced positive topline results from its pivotal Phase 2 REACH1 trial evaluating ruxolitinib (Jakafi ® ) in combination with corticosteroids for patients with steroid-refractory acute graft-versus-host disease (GVHD). The study met its primary endpoint , with a 55%...

Read More

June 21, 2018

0

Learning from Pfizer Acquisition. Regeneron to Fight Zika and More

Pfizer accepted to pay $14 billion in cash to acquire Medivation. It is important for investors to know what Pfizer is after with regard to this acquisition so that investors could sense the current deep-pocketed biopharmaceutical firms’ preferences in selecting...

Read More

August 23, 2016

0

Exploring two clinical-stage firms with new, different approaches to treatments

SOPHIRIS BIO AND NANOBIOTIX SOPHIRIS BIO  Sophiris Bio (SPHS) has a product called Topsalysin (PRX302) in Phase 2 clinical trial for the treatment of localized prostate. The product is in Phase 3 clinical trial for lower urinary tract symptoms of...

Read More

June 27, 2018

0

Cellectis Allogeneic “Off-the-Shelf” CAR T Candidate is Back in Clinical Trial

A couple of days ago, Cellectis (CLLS) , which uses its own proprietary gene editing technology known as “transcription activator-like effector nuclease (TALEN®)” in developing immunotherapies, received the following good news: The FDA has lifted the clinical hold, which the...

Read More

November 9, 2017

0

Halozyme: Helping Immunotherapy Products. Abeona: An Attractive Newcomer to the Stock Market

Halozyme Therapeutics ( HALO )  announced that it will present nonclinical data at the 32 nd  Annual Meeting of the Society for Immunotherapy of Cancer (SITC) which demonstrate the potential for PEGPH20, Halozyme's pegylated recombinant human hyaluronidase, to increase the...

Read More

November 10, 2017

0

Why Vertex added over $20 to its stock price today

Health Canada Approves PrSYMDEKO™ For People Ages 12 and Older With Certain CFTR Gene Mutations Vertex (VRTX) announced that Health Canada approved SYMDEKO™ (tezacaftor/ivacaftor and ivacaftor) for treating the underlying cause of cystic fibrosis (CF) in people ages 12 and older who have...

Read More

June 29, 2018

0

Exelixis liver cancer results are gratifying, so do not worry if some pretend they do not like them

The New England Journal of Medicine ( NEJM ) published results from the CELESTIAL phase 3 pivotal trial of Exelixis (EXEL) product Cabometyx® ( cabozantinib) in previously treated patients with advanced hepatocellular carcinoma (HCC) . The data demonstrate that Cabometyx...

Read More

July 5, 2018

0

  • Previous
  • 1
  • 2
  • ...
  • 37
  • 38
  • 39
  • ...
  • 172
  • 173
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy